Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics To Award Free Sequencing Under Cancer Grant Program

Premium

This story was originally published June 30.

Complete Genomics this week launched a cancer grant program in which it will award four "innovative cancer research projects" with whole-genome sequencing of four matched tumor/normal pairs.

The company will select two entries from the US and two from Europe.

Applications are due by July 29 and winners will be notified after Aug. 12. Further information about the program is available here.

While only four winners will be chosen by the company's internal panel of scientific experts, all applicants will be eligible for a discount on a whole-human genome sequencing project, although the company did not disclose how much of a discount.

Complete Genomics CEO Cliff Reid said in a statement that the projects would help "gain insights into the characterization and possible treatment" of cancer.

Reid has often cited cancer sequencing as a key opportunity for the company and earlier this year disclosed that the firm is developing a "cancer product" to identify differences between tumor and normal cells that it intends to launch some time this year (CSN 3/16/2011).

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.